-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nimoli beads are resistant to il-31 recepposes alpha sub-units in targeted adpogenic dermatitis (AD).
this study was designed to evaluate new drug strategies for Nemorydin monoantigen in AD patients.
We conducted a 24-week randomized, double-blind, multi-center study in which adults with moderate to severe AD, severe itching, and inadequate local treatment control were injected every 4 weeks with subdermal injections of Nemoricin monotherapy (10, 30 and 90 mg) and placebo, local corticosteroids.
the eczema area and severity index (EASI), the Itch Peak (PP) numerical score sheet (NRS), and the Researcher Global Assessment (IGA).
standard security assessment was carried out.
results showed that Nimoli beads improved EASI, IGA and/or NRS-itch scores, with a dose of 30 mg being the most effective.
Compared to placebos, Nimolidin (30mg) reduced the EASI score at week 24 (-68.8% vs -52.1%, P .016);
had a significant improvement as early as week 4 (P s .028), and at week 16, the IGA 0/1 rate of 30 mg nemodin monothecera was significantly higher than that of placebo (33.1) 3% vs 12.3%, P - .008), but not in week 24 because of increased placebo/local corticosteroid effect (36.8% vs 21.1%, P - .06).
in Week 16 (-68.6% vs .34.3%, P.lt; .0001) and weeks 24 (-67.3% vs -35.8%, P .lt; .0001), 30mg of nemorydin monothecetics improved relative to placebo PP-NRS scores, with significant differences to week 1 (P .lt; .001).
in weeks 16 (P s .001) and week 24 (P s .01), the 30mg nemory beads were more resistant to NRS than the placebo (down by 4 points).
nemoli beads are safe and well tolerated.
most common adverse events are nasopharyngitis and upper respiratory tract infections.
summary, the results of the study show that Nimoli beads can quickly and continuously improve skin inflammation and itching symptoms in AD patients, with maximum efficacy observed at 30 mg doses.
safety of the Nemoli beads is acceptable.
.
